2026 RNDS | Latest Updates from the METEOROID Trial @wearesrna
2026 RNDS | Latest Updates from the METEOROID Trial  @wearesrna
Uploaded October 2026 | Updated November 2026, 1 day ago
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Eoin Flanagan, MD, of Mayo Clinic joined remotely to share results from the phase three METEOROID trial of satralizumab, an interleukin-6 receptor blocker, in relapsing MOG antibody disease (MOGAD) [00:00:05]. He explained how interleukin-6 signaling relates to MOG antibody production and the blood-brain barrier [00:01:02], then described the randomized, double-blind design, which enrolled 132 people age 12 and older with relapsing MOGAD [00:04:15]. Dr. Flanagan reviewed the results, including a 68% reduction in the risk of a new relapse with satralizumab compared with placebo, along with fewer new MRI lesions [00:07:59]. He closed with safety findings that were similar between the two groups and thanked the participants and investigators [00:10:58].

Eoin Flanagan, MD, is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, Minnesota. He completed medical school at University College Dublin in 2005, then a neurology residency, fellowships in neuroimmunology, and a master's in clinical and translational science at Mayo Clinic. His clinical expertise and research focus on inflammatory myelopathies and their imaging patterns, MOGAD, neuromyelitis optica spectrum disorder, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH R01 grant studying MOGAD.

00:00 Welcome and Introduction
01:02 How Satralizumab Works
01:58 Why a Trial Was Needed
04:15 How the Trial Was Designed
04:49 Who Took Part
07:59 Main Results on Relapses
09:28 Other Measures and MRI Findings
10:58 Safety and Tolerability
11:51 Summary of the Trial
13:19 Thanks to Participants and Closing
2026 RNDS | Latest Updates from the METEOROID Trial2024 RNDS | Care for the Caregiver1212. The Role of Physicians and Patients in Legislative Advocacy2026 RNDS | Welcome Remarks and Conference Orientation2024 RNDS | Plasma Exchange for Acute Inflammatory Demyelination: How We Got Here and Where to Next?2026 RNDS | CAR-T Trials for NMOSD2024 RNDS | Rare Neuroimmune Disorders: Diagnostic Criteria2024 RNDS | Management of Visual Symptoms2024 RNDS | Management of Neuropathic Pain: Medical and Surgical Options2023 RNDS | A conversation on disability and rare neuroimmune disorders2026 RNDS | New Diagnostic Criteria Update: NMOSD and Criteria Q&A202. Dr. Michael Levy
SRNA |

2026 RNDS | Latest Updates from the METEOROID Trial

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER